APTOF
Price
$1.68
Change
-$0.00 (-0.00%)
Updated
May 22 closing price
Capitalization
4.5M
MDGL
Price
$273.35
Change
-$3.89 (-1.40%)
Updated
May 22 closing price
Capitalization
6.07B
75 days until earnings call
Interact to see
Advertisement

APTOF vs MDGL

Header iconAPTOF vs MDGL Comparison
Open Charts APTOF vs MDGLBanner chart's image
Aptose Biosciences
Price$1.68
Change-$0.00 (-0.00%)
Volume$1.4K
Capitalization4.5M
Madrigal Pharmaceuticals
Price$273.35
Change-$3.89 (-1.40%)
Volume$286.48K
Capitalization6.07B
APTOF vs MDGL Comparison Chart
Loading...
APTOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APTOF vs. MDGL commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APTOF is a Hold and MDGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (APTOF: $1.68 vs. MDGL: $273.35)
Brand notoriety: APTOF and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APTOF: 9% vs. MDGL: 85%
Market capitalization -- APTOF: $4.5M vs. MDGL: $6.07B
APTOF [@Biotechnology] is valued at $4.5M. MDGL’s [@Biotechnology] market capitalization is $6.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $111.46B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APTOF’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • APTOF’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than APTOF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APTOF’s TA Score shows that 1 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).

  • APTOF’s TA Score: 1 bullish, 1 bearish.
  • MDGL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, APTOF is a better buy in the short-term than MDGL.

Price Growth

APTOF (@Biotechnology) experienced а -4.55% price change this week, while MDGL (@Biotechnology) price change was -6.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.00%. For the same industry, the average monthly price growth was +5.57%, and the average quarterly price growth was -1.69%.

Reported Earning Dates

APTOF is expected to report earnings on Mar 28, 2025.

MDGL is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+3.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.07B) has a higher market cap than APTOF($4.5M). APTOF YTD gains are higher at: 645.672 vs. MDGL (-11.414). APTOF has higher annual earnings (EBITDA): -24.82M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. APTOF (3.32M). APTOF has less debt than MDGL: APTOF (10.7M) vs MDGL (120M). MDGL has higher revenues than APTOF: MDGL (317M) vs APTOF (0).
APTOFMDGLAPTOF / MDGL
Capitalization4.5M6.07B0%
EBITDA-24.82M-376.15M7%
Gain YTD645.672-11.414-5,657%
P/E RatioN/AN/A-
Revenue0317M-
Total Cash3.32M843M0%
Total Debt10.7M120M9%
FUNDAMENTALS RATINGS
APTOF vs MDGL: Fundamental Ratings
APTOF
MDGL
OUTLOOK RATING
1..100
155
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
10040
SMR RATING
1..100
9994
PRICE GROWTH RATING
1..100
3462
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
27n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (63) in the Pharmaceuticals Other industry is in the same range as APTOF (89) in the Biotechnology industry. This means that MDGL’s stock grew similarly to APTOF’s over the last 12 months.

MDGL's Profit vs Risk Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for APTOF (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than APTOF’s over the last 12 months.

MDGL's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as APTOF (99) in the Biotechnology industry. This means that MDGL’s stock grew similarly to APTOF’s over the last 12 months.

APTOF's Price Growth Rating (34) in the Biotechnology industry is in the same range as MDGL (62) in the Pharmaceuticals Other industry. This means that APTOF’s stock grew similarly to MDGL’s over the last 12 months.

APTOF's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that APTOF’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APTOFMDGL
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bearish Trend 25 days ago
90%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 25 days ago
75%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 25 days ago
74%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 25 days ago
90%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
N/A
Bullish Trend 15 days ago
77%
Declines
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
APTOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JD33.690.04
+0.12%
JD.com
CLMB107.11N/A
N/A
Climb Global Solutions
BRLT1.39N/A
N/A
Brilliant Earth Group
NTST15.48-0.11
-0.71%
NetSTREIT Corp
HMY15.18-0.16
-1.04%
Harmony Gold Mining Company Limited

APTOF and

Correlation & Price change

A.I.dvisor tells us that APTOF and BDTX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APTOF and BDTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APTOF
1D Price
Change %
APTOF100%
N/A
BDTX - APTOF
30%
Poorly correlated
+1.48%
LOGC - APTOF
28%
Poorly correlated
-3.98%
MDGL - APTOF
28%
Poorly correlated
-1.40%
SLNO - APTOF
28%
Poorly correlated
N/A
HUMA - APTOF
27%
Poorly correlated
+2.56%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-1.40%
KANT - MDGL
62%
Loosely correlated
N/A
ALXO - MDGL
56%
Loosely correlated
N/A
ZNTL - MDGL
51%
Loosely correlated
N/A
CGEM - MDGL
50%
Loosely correlated
+0.25%
MBIO - MDGL
50%
Loosely correlated
+7.56%
More